Commitments And Contingencies (Narrative) (Details) (USD $)	3 Months Ended					0 Months Ended	1 Months Ended	3 Months Ended		3 Months Ended		1 Months Ended	3 Months Ended							0 Months Ended		3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013		Dec. 31, 2013	Feb. 22, 2014 Department of Health and Human Services Subpoena and Related Matters [Member]	Sep. 30, 2013 Department of Health and Human Services Subpoena and Related Matters [Member]	Mar. 31, 2014 Maximum [Member] Paragraph IV certification on frova [Member]	Mar. 31, 2014 Watson Settlement Agreement [Member]	Mar. 31, 2014 Grunenthal Agreement [Member] Regulatory and commercial milestone [Member]	Mar. 31, 2013 Grunenthal Agreement [Member] Regulatory and commercial milestone [Member]	Jul. 31, 2013 AMS [Member] Vaginal mesh cases [Member]	Mar. 31, 2014 AMS [Member] Vaginal mesh cases [Member]	Dec. 31, 2013 AMS [Member] Vaginal mesh cases [Member]	Mar. 31, 2013 AMS [Member] Vaginal mesh cases [Member]	Dec. 31, 2013 Prepaid Expenses and Other Current Assets [Member] AMS [Member] Vaginal mesh cases [Member]	Mar. 31, 2014 Accrued Expenses [Member] AMS [Member] Vaginal mesh cases [Member]	May 02, 2014 Subsequent Event [Member] MCP cases [Member] Pending_Cases	May 02, 2014 Subsequent Event [Member] Propoxyphene cases [Member] Pending_Cases	Apr. 30, 2014 Subsequent Event [Member] AMS [Member] Vaginal mesh cases [Member] settled_cases	Apr. 25, 2014 Subsequent Event [Member] AMS [Member] Vaginal mesh cases [Member] Pending_Cases	Mar. 31, 2014 Teikoku Seiyaku Co Ltd [Member] Japanese_Facilities	Mar. 31, 2013 Teikoku Seiyaku Co Ltd [Member]	Mar. 31, 2014 Watson Laboratories, Inc [Member]	Aug. 03, 2012 Watson Laboratories, Inc [Member]
Commitments And Contingencies [Line Items]
Amounts incurred by Endo for A&P Expenditures	$ 2,100,000		$ 2,100,000
Japanese facilities for commercial sale in the United States																						2
Termination of agreement notice period (days)																						30 days
Termination of agreement written notice after expiration date, (in days)																						180 days
Percentage of royalty rate of net sales																							6.00%
Payments for royalties																						1,800,000	11,000,000
Royalty payable																						1,800,000
Wholesaler price discount percentage																									50.00%
License and supply payment period										45 days
Additional milestone payment recognized										7,800,000	8,200,000
Payment for contingent consideration	0		(5,000,000)
Loss contingency, loss in period	641,100,000	[1]	76,532,000	[1]		193,000,000
Loss Contingency, Civil Claims Settlement						171,800,000
Loss Contingency, Criminal Claims Settlement						20,800,000
Litigation Settlement, Amount							1,400,000										600,000,000			830,000,000
Percentage of royalty rate of gross sales (percent)																								25.00%
Royalty Revenue																								38,200,000
Estimated litigation liability									0
Increase (decrease) in accounts payable	59,916,000		136,323,000
Accounts payable	298,099,000				263,241,000
Patents expiration date								2015
Pending claims, number																		600	40		23,500
Loss Contingency, Claims Settled, Number																				20,000
Escrow Deposits Related to Litigation												54,500,000				8,400,000
Product Liability Accrual, Period Expense													1,100,000,000
Litigation-related and other contingencies	626,151,000		68,232,000										600,000,000		100,000,000
Release From Escrow Related To Litigation													$ 3,100,000	$ 43,000,000
Cases on appeal																			75
Lawsuit filing period	45 days
Stay of approval period, Hatch-Waxman Act	30 months

[1] These amounts includes charges for Litigation-related and other contingencies, consisting primarily of mesh-related product liability charges, as well as mesh litigation-related defense costs for the three months ended March 31, 2014 and 2013.